Kelsey Goodwin
Stock Analyst at Guggenheim
(0.49)
# 3,887
Out of 4,735 analysts
15
Total ratings
30%
Success rate
-15.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNLX Genelux | Initiates: Buy | $8 | $2.89 | +176.82% | 1 | Oct 29, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $99 → $105 | $78.28 | +34.13% | 2 | Sep 16, 2024 | |
| URGN UroGen Pharma | Initiates: Buy | $40 | $10.19 | +292.54% | 1 | Aug 22, 2024 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $3.00 | - | 1 | Jul 31, 2024 | |
| TSVT 2seventy bio | Downgrades: Neutral | n/a | $2.45 | - | 4 | Sep 13, 2023 | |
| ACLX Arcellx | Maintains: Buy | n/a | $66.57 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $34.67 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $5.88 | - | 1 | Oct 31, 2022 | |
| IPSC Century Therapeutics | Initiates: Buy | $15 | $0.90 | +1,571.87% | 1 | Oct 31, 2022 |
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.89
Upside: +176.82%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $99 → $105
Current: $78.28
Upside: +34.13%
UroGen Pharma
Aug 22, 2024
Initiates: Buy
Price Target: $40
Current: $10.19
Upside: +292.54%
MacroGenics
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.00
Upside: -
2seventy bio
Sep 13, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.45
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $66.57
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $34.67
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $5.88
Upside: -
Century Therapeutics
Oct 31, 2022
Initiates: Buy
Price Target: $15
Current: $0.90
Upside: +1,571.87%